Sandler Laura Lee 4
4 · Oruka Therapeutics, Inc. · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
Oruka Therapeutics (ORKA) COO Laura Lee Sandler Sells 600 Shares
What Happened
Laura Lee Sandler, Chief Operating Officer of Oruka Therapeutics (ORKA), sold 600 shares on 2026-03-16 at $41.30 per share, generating $24,780 in proceeds. The transaction is a sale (code S) and was reported on a Form 4 filed 2026-03-17.
Key Details
- Transaction date and price: 2026-03-16 — 600 shares sold at $41.30 each.
- Total proceeds: $24,780.
- Shares owned after transaction: Not specified in the filing.
- Footnote: The sale was effected pursuant to Oruka’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding arising from the vesting of restricted stock units (RSUs).
- Filing timeliness: Form 4 was filed on 2026-03-17 (one day after the transaction), which is within the normal reporting window.
Context
Sell-to-cover transactions are routine tax-withholding sales tied to RSU vesting and do not necessarily indicate a personal view on the company’s prospects. For retail investors, purchases are typically a stronger signal than these kinds of withholding sales.
Insider Transaction Report
Form 4
Sandler Laura Lee
Chief Operating Officer
Transactions
- Sale
Common Stock
[F1]2026-03-16$41.30/sh−600$24,780→ 236,984 total
Footnotes (1)
- [F1]The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.
Signature
/s/ Paul Quinlan, as attorney-in-fact for Laura Sandler|2026-03-17